R H Blum

Author PubWeight™ 55.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996 9.68
2 Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994 9.54
3 High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000 4.60
4 Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 1974 2.77
5 A clinical review of bleomycin--a new antineoplastic agent. Cancer 1973 2.53
6 Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993 2.28
7 Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998 1.94
8 Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989 1.25
9 A randomized multicenter study of remifentanil compared with halothane in neonates and infants undergoing pyloromyotomy. I. Emergence and recovery profiles. Anesth Analg 2001 1.19
10 Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980 1.19
11 High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med 1980 1.02
12 Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med 1985 0.99
13 Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Clin Cancer Res 1997 0.95
14 Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 1992 0.87
15 Hexamethylmelamine--a new drug with activity in solid tumors. Eur J Cancer 1973 0.85
16 Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32. Recent Results Cancer Res 1981 0.83
17 A therapeutic trial of maytansine. Cancer Clin Trials 1978 0.81
18 Maytansine: a phase I study of an ansa macrolide with antitumor activity. Cancer Treat Rep 1978 0.81
19 Survival of patients with localized high-grade soft tissue sarcoma with multimodality therapy. A matched control study. Cancer 1983 0.81
20 Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. J Immunother Emphasis Tumor Immunol 1994 0.81
21 Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients. Cancer Chemother Pharmacol 1989 0.80
22 New chemotherapeutic agents--bleomycin and adriamycin. CA Cancer J Clin 1975 0.80
23 Management of cancer pain with oral controlled-release morphine sulfate. J Clin Pharmacol 1987 0.79
24 A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer. Am J Clin Oncol 1991 0.79
25 A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer 1998 0.78
26 Serial studies of cardiac function in patients receiving adriamycin. Cancer Treat Rep 1978 0.78
27 Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog. Cancer Treat Rep 1979 0.78
28 A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer 1999 0.78
29 Role of chemotherapy in the treatment of lung cancer: evolving strategies for non-small cell histologies. Int J Radiat Oncol Biol Phys 1984 0.77
30 A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma. Am J Clin Oncol 1989 0.77
31 A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer. Cancer Treat Rev 1990 0.77
32 Cisplatin and vinblastine chemotherapy for metastatic non-small cell carcinoma followed by irradiation in patients with regional disease. Cancer Treat Rep 1986 0.76
33 Phase I trial of bruceantin. Cancer Treat Rep 1980 0.76
34 Phase I trial of escalating dose doxorubicin administered concurrently with alpha 2-interferon. Cancer Res 1988 0.75
35 Effect of adjuvant central iv hyperalimentation on the survival and response to treatment of patients with small cell lung cancer: a randomized trial. Cancer Treat Rep 1985 0.75
36 Overreaction to latex allergy? Anesth Analg 1997 0.75
37 Phase I and preliminary phase II study of neocarzinostatin. Cancer Treat Rep 1978 0.75
38 Feasibility of combined modality therapy for localized high-grade soft tissue sarcomas in adults. Int J Radiat Oncol Biol Phys 1979 0.75
39 Legislators' views on alcoholism: some dimensions relevant to making new laws. Q J Stud Alcohol 1965 0.75
40 Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion. N Engl J Med 1984 0.75
41 Activity of epirubicin in pancreatic carcinoma. Cancer Treat Rep 1986 0.75
42 Evaluation of a sequential 5-FU and hydroxyurea combination in advanced bowel cancer. Cancer Treat Rep 1984 0.75
43 Chemotherapy for locally advanced lung cancer: rationale and issues. Prog Clin Biol Res 1985 0.75
44 Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586). Cancer J Sci Am 2000 0.75
45 Psychological processes in preparing contemporary biography. Biography 1981 0.75
46 Current status of American studies with bleomycin. Prog Biochem Pharmacol 1976 0.75
47 Adriamycin plus alkylating agents in the treatment of metastatic breast cancer. Cancer 1977 0.75
48 Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial. Invest New Drugs 1986 0.75
49 Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD). Cancer 1980 0.75
50 Phase I study of the combination of alpha-2 interferon and cisplatinum. J Biol Response Mod 1989 0.75
51 Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA). Cancer Treat Rep 1981 0.75
52 Phase I-II study of the continuous infusion of doxorubicin in the treatment of non-small cell lung cancer. Cancer Treat Rep 1984 0.75
53 Drugs and public policy. Let the punishment eclipse the crime. Am J Orthopsychiatry 1973 0.75
54 Phase II trial of cyclophosphamide and cis-platinum for non-small cell bronchogenic carcinoma. Am J Clin Oncol 1984 0.75
55 Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor. J Cancer Res Clin Oncol 1992 0.75
56 Phase II trials of interferons-alpha and -beta in advanced sarcomas. J Interferon Res 1992 0.75
57 Lung cancer. Chemotherapy as curative treatment. N Y State J Med 1981 0.75
58 Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule. Cancer Res 1982 0.75
59 [A scientist looks at drugs]. Bull Infirm Cathol Can 1969 0.75
60 Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol 1994 0.75
61 Phase I trial of combination therapy with PALA and 5-FU. Cancer Treat Rep 1981 0.75
62 Future clinical investigations with anthracycline antibiotics in relation to daunorubicin. Cancer Treat Rep 1981 0.75